Aldeyra Therapeutics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2004

Location

Lexington MA US

Primary Industry

Biotechnology

About

Based in Massachusetts, US, and founded in 2004 by CEO Todd C. Brady, Aldeyra Therapeutics, Inc., aka Aldeyra Therapeutics, develops pharmaceuticals that modulate immunological systems instead of directly inhibiting or activating single protein targets to minimize toxicity to treat immune-mediated diseases. In December 2012, Aldeyra Therapeutics, Inc. raised USD 4.79 million in Series B funding from Johnson & Johnson and Domain Associates. The company's product line includes RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases such as dry eye disease and allergic conjunctivitis. In addition, the firm also offers products for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, other retinal diseases, autoimmune disease, and cancer.

Current Investors

Domain Associates, Johnson & Johnson Innovation

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Biotechnology

Website

www.aldeyra.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.